Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis

Leverages proprietary pan-amyloid targeting agents with potential to diagnose and reverse the underlying pathology of systemic amyloid diseases, including AL and ATTR amyloidosis SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Venture Capital Attralus, amyloidosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news